Exelixis Inc(EXEL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 18.04 | EPS (ttm) | 3.18 | Insider Own | 3.18% | Shs Outstand | 248.9M | Perf Week | -1.88% |
| Market Cap | 14.23B | Forward P/E | 13.85 | EPS next Y | 18.04% | Insider Trans | -2.82% | Shs Float | 239.9M | Perf Month | 11.88% |
| Enterprise Value | 13.56B | PEG | 0.86 | EPS next Q | 0.89 | Inst Own | 105.77% | Short Float | 11.68% | Perf Quarter | 9.22% |
| Income | 0.86B | P/S | 5.84 | EPS this Y | 14.05% | Inst Trans | -1.23% | Short Ratio | 10.99 | Perf Half Y | 37.56% |
| Sales | 2.44B | P/B | 7.75 | EPS next 5Y | 16.11% | ROA | 33.28% | Short Interest | 28.03M | Perf YTD | 31.03% |
| Book/sh | 7.41 | P/C | 16.95 | EPS past 3/5Y | 70.35% 51.19% | ROE | 44.39% | 52W High | -3.83% ($59.72) | Perf Year | 52.33% |
| Cash/sh | 3.39 | P/FCF | 12.14 | Sales past 3/5Y | 12.93% 18.63% | ROIC | 42.82% | 52W Low | 70.14% ($33.76) | Perf 3Y | 159.75% |
| Dividend Est. | - | EV/EBITDA | 13.29 | EPS Y/Y TTM | 53.08% | Gross Margin | 96.48% | Volatility(W/M) | 2.79% 2.73% | Perf 5Y | 187.73% |
| Dividend TTM | - | EV/Sales | 5.57 | Sales Y/Y TTM | 9.23% | Oper. Margin | 40.72% | ATR (14) | 1.56 | Perf 10Y | 379.38% |
| Dividend Ex-Date | - | Quick Ratio | 3.38 | EPS Q/Q | 25.63% | Profit Margin | 35.33% | RSI (14) | 56.39 | Recom | 2.43 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.46 | Sales Q/Q | 10.63% | SMA20 | 3.65% ($55.41) | Beta | 0.47 | Target Price | $53.69 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/8/5 | SMA50 | 3.96% ($55.24) | Rel Volume | 0.64 | Prev Close | $58.33 |
| Employees | 1077 | LT Debt/Eq | 0.09 | EPS/Sales Surpr. | 6.63% -1.21% | SMA200 | 19.93% ($47.89) | Avg Volume(3M) | 2.55M | Price | $57.43 |
| IPO | 2000/4/11 | Option/Short | Yes/Yes | Trades | 21250 | Volume | 1,628,982 | Change | -1.54% |
Company
EXEL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A commercial-stage biopharmaceutical company headquartered in California, USA, specializing in oncology. Its key product is Cabometyx, a targeted cancer therapy used to treat kidney cancer, and the company generates revenue while developing follow-up oncology drugs.
Over the past 1 year, on the higher side
4% below its 1-year high.
EXEL makes money exceptionally well
40.72% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +14.1% this year.
Tap to view numbers
The price looks about right
Trading at 18.0 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +159.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 105.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IDNA 0.04%
FBT 0.03%
SAWG 0.03%
PBE 0.03%
CANC 0.03%It ranks #4 in the industry
Based on market cap of $14B.
EXEL $14B PER 18.0
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is EXEL?
EXEL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EXEL?
The market cap of EXEL is approximately $14.2B, ranking 748 within its sector.
What is the P/E ratio of EXEL?
EXEL has a P/E ratio of approximately 18.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for EXEL?
EXEL has recorded a 52-week high of $59.72 and a low of $33.76.
